Gout, flares, and allopurinol use: a population-based study.
Allopurinol
Gout
Gout flares
Population study
Prevalence
Self-reported
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
31 05 2019
31 05 2019
Historique:
received:
29
11
2018
accepted:
15
05
2019
entrez:
2
6
2019
pubmed:
4
6
2019
medline:
28
5
2020
Statut:
epublish
Résumé
There is a paucity of community-based data regarding the prevalence and impact of gout flares as these may often be self-managed. The aim of this study was to determine the prevalence of self-reported gout and gout flares, the use of urate-lowering therapy (ULT), and the association of gout flares with health-related quality of life (HRQoL) in a large community sample. Covariate associations with flare frequency and allopurinol use were also examined. The South Australian Health Omnibus Survey is an annual, face-to-face population-based survey. Data collected in the 2017 survey included self-reported medically diagnosed gout, allopurinol use (first-line ULT in Australia), and gout attacks (flares) in the last 12 months, in addition to sociodemographic variables and health-related quality of life (HRQoL, SF-12). Data were weighted to the Australian Bureau of Statistics 2016 census data to reflect the South Australian population. Participants 25 years and over (n = 2778) were included in the analysis. The prevalence of gout was 6.5% (95%CI 5.5, 7.5). Amongst participants with gout, 37.1% (95%CI 29.6, 45.3) reported currently using allopurinol, while 23.2% (95%CI 16.9, 21.0) reported prior use (38% discontinuation rate). Frequent flares (≥ 2 in the last year) were reported by 25% of participants with gout and were more likely with younger age, higher body mass index, and current allopurinol use (p < 0.05). The frequency of gout flares was associated with a lower physical HRQoL (p = 0.012). Current allopurinol use was reported by 51% of participants with frequent gout flares. Flares were frequently reported by people with gout in the community. Gout flares were associated with reduced physical HRQoL. Almost one half of people with frequent gout flares were not receiving allopurinol, and current allopurinol use was associated with frequent gout flares, suggesting undertreated disease and suboptimal use of ULT. Determining covariate associations with flares and ineffective allopurinol use may identify means of improving treatment and reducing flares.
Sections du résumé
BACKGROUND
There is a paucity of community-based data regarding the prevalence and impact of gout flares as these may often be self-managed. The aim of this study was to determine the prevalence of self-reported gout and gout flares, the use of urate-lowering therapy (ULT), and the association of gout flares with health-related quality of life (HRQoL) in a large community sample. Covariate associations with flare frequency and allopurinol use were also examined.
METHODS
The South Australian Health Omnibus Survey is an annual, face-to-face population-based survey. Data collected in the 2017 survey included self-reported medically diagnosed gout, allopurinol use (first-line ULT in Australia), and gout attacks (flares) in the last 12 months, in addition to sociodemographic variables and health-related quality of life (HRQoL, SF-12). Data were weighted to the Australian Bureau of Statistics 2016 census data to reflect the South Australian population. Participants 25 years and over (n = 2778) were included in the analysis.
RESULTS
The prevalence of gout was 6.5% (95%CI 5.5, 7.5). Amongst participants with gout, 37.1% (95%CI 29.6, 45.3) reported currently using allopurinol, while 23.2% (95%CI 16.9, 21.0) reported prior use (38% discontinuation rate). Frequent flares (≥ 2 in the last year) were reported by 25% of participants with gout and were more likely with younger age, higher body mass index, and current allopurinol use (p < 0.05). The frequency of gout flares was associated with a lower physical HRQoL (p = 0.012). Current allopurinol use was reported by 51% of participants with frequent gout flares.
CONCLUSION
Flares were frequently reported by people with gout in the community. Gout flares were associated with reduced physical HRQoL. Almost one half of people with frequent gout flares were not receiving allopurinol, and current allopurinol use was associated with frequent gout flares, suggesting undertreated disease and suboptimal use of ULT. Determining covariate associations with flares and ineffective allopurinol use may identify means of improving treatment and reducing flares.
Identifiants
pubmed: 31151457
doi: 10.1186/s13075-019-1918-7
pii: 10.1186/s13075-019-1918-7
pmc: PMC6544947
doi:
Substances chimiques
Gout Suppressants
0
Allopurinol
63CZ7GJN5I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
132Références
Rheumatology (Oxford). 2011 May;50(5):973-81
pubmed: 21228059
Br J Clin Pharmacol. 2016 Feb;81(2):277-89
pubmed: 26451524
Rheumatol Int. 2014 Jul;34(7):963-70
pubmed: 24390636
Arthritis. 2015;2015:607472
pubmed: 26357571
Arthritis Res Ther. 2017 Aug 9;19(1):181
pubmed: 28793914
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
J Clin Rheumatol. 2009 Feb;15(1):3-7
pubmed: 19125135
J Rheumatol. 2015 Sep;42(9):1702-7
pubmed: 26233513
Health Qual Life Outcomes. 2017 Dec 21;15(1):244
pubmed: 29268792
Ann Rheum Dis. 2008 May;67(5):609-13
pubmed: 17728328
Mayo Clin Proc. 2006 Jul;81(7):925-34
pubmed: 16835972
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447-61
pubmed: 23024029
Arthritis Rheumatol. 2019 Jun;71(6):991-999
pubmed: 30618180
Intern Med J. 2016 May;46(5):566-73
pubmed: 26765205
J Rheumatol. 2009 May;36(5):1032-40
pubmed: 19369467
J Rheumatol. 2011 Jan;38(1):135-41
pubmed: 21123328
BMC Med. 2017 Jul 3;15(1):123
pubmed: 28669352
BMC Rheumatol. 2018 May 30;2:14
pubmed: 30886965
Health Qual Life Outcomes. 2012 Sep 22;10:117
pubmed: 22999027
BMC Musculoskelet Disord. 2017 Mar 14;18(1):108
pubmed: 28292303
Ann Rheum Dis. 2014 Jan;73(1):177-82
pubmed: 23313809
Clin Ther. 2017 Feb;39(2):430-441
pubmed: 28089200
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46
pubmed: 23024028
BMJ Open. 2015 Jun 24;5(6):e007214
pubmed: 26109113
Joint Bone Spine. 2015 Oct;82 Suppl 1:eS2-8
pubmed: 26717799
Aust Fam Physician. 2016 May;45(5):299-302
pubmed: 27166465
J Rheumatol. 2016 Jan;43(1):144-9
pubmed: 26568590
Ann Rheum Dis. 2017 Jan;76(1):29-42
pubmed: 27457514
Arthritis Rheumatol. 2018 Mar;70(3):462-467
pubmed: 29161469
Arthritis Care Res (Hoboken). 2017 Apr;69(4):561-566
pubmed: 27331767
Rheumatology (Oxford). 2007 Sep;46(9):1441-4
pubmed: 17586863
Eur J Epidemiol. 2015 Jan;30(1):19-33
pubmed: 25064615
Arthritis Rheum. 2011 Oct;63(10):3136-41
pubmed: 21800283
Nat Rev Rheumatol. 2015 Nov;11(11):649-62
pubmed: 26150127
Rheumatology (Oxford). 2018 Sep 1;57(9):1641-1650
pubmed: 29893941
Ann Rheum Dis. 2015 Apr;74(4):661-7
pubmed: 24431399
PLoS One. 2012;7(6):e39321
pubmed: 22723994
Acad Emerg Med. 2018 Apr;25(4):467-469
pubmed: 29479769
Arthritis Rheum. 2012 Dec;64(12):4004-11
pubmed: 23023818
Ann Rheum Dis. 2007 Oct;66(10):1311-5
pubmed: 17504843
Rheumatology (Oxford). 2005 Aug;44(8):1038-42
pubmed: 15870145